Report: Global NSCLC drug market will reach $7.9B in 9 years The global market for nonsmall-cell lung cancer treatments is predicted to expand at a compound annual growth rate of 3.3%, from $5.7 billion last year to $7.9 billion in 2022, according to a report from GlobalData. Analysts say Bristol-Myers Squibb's nivolumab, which is anticipated to be commercialized in 2015, has the potential to outsell blockbuster rivals and lead the overall NSCLC market by 2022. PharmaTimes (U.K.) (7/15) | NCI releases cancer genetics database The National Cancer Institute opened worldwide access to the largest-ever database of cancer-related genetic information based on the results of sequencing 60 human cancer cell lines. Researchers can mine the data to connect therapies with genomic variations. Reuters (7/15), HealthDay News (7/15) FDA needs more time to review Merck's sugammadex injection The FDA called off a meeting of outside advisers who were set to decide Thursday whether to grant approval recommendation for Merck's sugammadex, an injectable drug designed to reverse the effects of muscle relaxants during surgery. Merck said the agency asked for more time to evaluate clinical data linking the drug to allergic reactions. Reuters (7/16) Head and neck cancer combo treatment includes measles virus A study published in the journal Radiotherapy & Oncology used a bioengineered measles virus to target cancer cells of colorectal carcinoma and head and neck cancer. A combination of measles virus, radioiodide, radiation treatment and gene-targeting drugs was used in the study as a treatment mix, which proved more effective than using the four treatments separately. Researchers genetically modified the measles virus to express a gene called sodium iodide symporter, which triggers the cancer cells to take up the radioactive iodides, which in turn treats the cancer. DrBicuspid.com (free registration) (7/15) Lamins essential in stem cell niche regulation Researchers from the Carnegie Institution for Science who studied fruit fly testes found that lamins, a type of nucleic structural protein, play a vital role in the organization of stem cell niches. "These findings could contribute to the study of diseases caused by lamina-based tissue degeneration. For example, different lamin mutations could disrupt the organization of different niches in the body, which then leads to degeneration in tissues," said Yixian Zheng, one of the study authors. Science World Report (7/13) | ThermoGenesis merges with Los Angeles-based cell therapy maker ThermoGenesis agreed to acquire cell-based therapy maker TotipotentRx for $18.6 million. The firms will join and be called Cesca Therapeutics, which will retain the ThermoGenesis ticker symbol KOOL. The deal is expected to be finalized in the fourth quarter. "By combining our cell-based device technologies with TotiRx's clinically validated therapeutic protocols and cell therapy kits for major therapeutic areas, we expect Cesca to be one of the first fully integrated regenerative medicine companies," ThermoGenesis CEO Matthew Plavan said. American City Business Journals/Sacramento, Calif. (7/16) | Indian President Mukherjee supports adoption of biotech crops Indian President Pranab Mukherjee called on the Indian Council of Agricultural Research to "contribute to the public discourse and provide clarity" on safety concerns about biotech crops and said biotechnology could revolutionize the nation's farming sector. "Development and introduction of GM crops has the potential to revolutionize agriculture. The concerns over their perceived risks should be addressed by following internationally accepted procedures for assessing safety parameters," Mukherjee said. Business Standard (India)/Press Trust of India (7/16) | | Industrial & Environmental | Biofuels to be studied in microgravity The University of California at San Diego's Microgravity Team has won a place on the NASA's "Vomit Comet" to test the combustion characteristics of biofuel in reduced gravity. The teams hopes the research will lead to better engines. BiofuelsDigest.com (7/15) | Join us Nov. 11-13 at the BIO Convention in China in Beijing! The BIO Convention in China brings together executives from biotechnology, pharmaceutical companies and investment firms from North America, Europe and Asia to meet and explore business opportunities with China's emerging biotech sector. BIO is renowned for its successful business development, partnering and investor meetings in North America, Europe and Asia. Partnering at this conference will be powered by BIO One-on-One Partnering, an interactive environment to intelligently search, contact and schedule private meetings with potential partners and investors. Learn more and register today. |  | Flattery is like cologne water, to be smelt, not swallowed." -- Josh Billings, American humorist | | The news summaries appearing in BIO SmartBrief are based on original information from news organizations and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The information is not compiled or summarized by BIO. Questions and comments should be directed to SmartBrief at bio@smartbrief.com. | Please contact one of our specialists for advertising opportunities, editorial inquiries, job placements, or any other questions.
| Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004 | | |
No comments:
Post a Comment